Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012

Description: Pre-Diabetes/Impaired Glucose Tolerance – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pre-Diabetes/Impaired Glucose Tolerance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pre-Diabetes/Impaired Glucose Tolerance. Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pre-Diabetes/Impaired Glucose Tolerance.
- A review of the Pre-Diabetes/Impaired Glucose Tolerance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pre-Diabetes/Impaired Glucose Tolerance pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pre-Diabetes/Impaired Glucose Tolerance.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pre-Diabetes/Impaired Glucose Tolerance pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Pre-Diabetes/Impaired Glucose Tolerance Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pre-Diabetes/Impaired Glucose Tolerance 7
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics under Development by Companies 9
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics under Investigation by Universities/Institutes 10
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Resverlogix Corp., H2 2012 15
Limerick BioPharma, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Drug Profile Updates 30
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Pre-Diabetes/Impaired Glucose Tolerance, H2 2012 7
Products under Development for Pre-Diabetes/Impaired Glucose Tolerance – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2366290/
Order by Fax - using the form below
Order by Post - print the order form below and send to

    Research and Markets,
    Guinness Centre,
    Taylors Lane,
    Dublin 8,
    Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2366290/
Office Code: SCD2I382

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp